Lytix Biopharma is a clinical-stage biotech company developing proprietary oncolytic peptides as a novel immune therapy to fight cancer. Its development program consists of LTX-315, the lead compound, currently being tested in two separate and independent Phase II clinical trials for patients with solid tumors; LTX-401; a second-generation compound, under preparation for entry into human clinical studies for patients with deep-seated lesions; a hypothesis-driven clinical program for the application of the entire class of oncolytic molecules in the setting of adoptive T-cell transfer (ATCT) technology; an early-stage investigation of oncolytic molecules in an undisclosed clinical setting. The company has a license to develop and commercialize LTX-315 for certain types of skin cancers.